| Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised … B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro, ... The Lancet 394 (10212), 1915-1928, 2019 | 2849 | 2019 |
| Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial J Bennouna, J Sastre, D Arnold, P Österlund, R Greil, E Van Cutsem, ... The lancet oncology 14 (1), 29-37, 2013 | 1408 | 2013 |
| Endocrine therapy plus zoledronic acid in premenopausal breast cancer M Gnant, B Mlineritsch, W Schippinger, G Luschin-Ebengreuth, ... New England Journal of Medicine 360 (7), 679-691, 2009 | 1295 | 2009 |
| Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ... New England Journal of Medicine 382 (7), 597-609, 2020 | 1233 | 2020 |
| Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 … R Jakesz, W Jonat, M Gnant, M Mittlboeck, R Greil, C Tausch, J Hilfrich, ... The Lancet 366 (9484), 455-462, 2005 | 1230 | 2005 |
| Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma A Engert, A Plütschow, HT Eich, A Lohri, B Dörken, P Borchmann, ... New England Journal of Medicine 363 (7), 640-652, 2010 | 1136 | 2010 |
| A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors M Filipits, M Rudas, R Jakesz, P Dubsky, F Fitzal, CF Singer, O Dietze, ... Clinical Cancer Research 17 (18), 6012-6020, 2011 | 837 | 2011 |
| Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor–positive breast cancer J Baselga, V Semiglazov, P van Dam, A Manikhas, M Bellet, ... Journal of Clinical Oncology 27 (16), 2630-2637, 2009 | 825 | 2009 |
| Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 … DV Engert A, Haverkamp H, Kobe C, Markova J, Renner C, GHS Group, ... LANCET 329 (9828), 1791-9, 2012 | 775* | 2012 |
| Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer NU Lin, V Diéras, D Paul, D Lossignol, C Christodoulou, HJ Stemmler, ... Clinical cancer research 15 (4), 1452-1459, 2009 | 774 | 2009 |
| Monoclonal gammopathy of undetermined significance: natural history in 241 cases RA Kyle The American journal of medicine 64 (5), 814-826, 1978 | 742 | 1978 |
| Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label … C Moreno, R Greil, F Demirkan, A Tedeschi, B Anz, L Larratt, M Simkovic, ... The Lancet Oncology 20 (1), 43-56, 2019 | 660 | 2019 |
| Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial M Gnant, G Pfeiler, PC Dubsky, M Hubalek, R Greil, R Jakesz, V Wette, ... The Lancet 386 (9992), 433-443, 2015 | 621 | 2015 |
| Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma H Tilly, F Morschhauser, LH Sehn, JW Friedberg, M Trněný, JP Sharman, ... New England Journal of Medicine 386 (4), 351-363, 2022 | 620 | 2022 |
| Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3 E Van Cutsem, R Labianca, G Bodoky, C Barone, E Aranda, B Nordlinger, ... Journal of Clinical Oncology 27 (19), 3117-3125, 2009 | 619 | 2009 |
| Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial M Gnant, B Mlineritsch, H Stoeger, G Luschin-Ebengreuth, D Heck, ... The lancet oncology 12 (7), 631-641, 2011 | 612 | 2011 |
| Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group … HT Eich, V Diehl, H Görgen, T Pabst, J Markova, J Debus, A Ho, B Dörken, ... Journal of Clinical Oncology 28 (27), 4199-4206, 2010 | 539 | 2010 |
| Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma MR Bishop, M Dickinson, D Purtill, P Barba, A Santoro, N Hamad, K Kato, ... New England Journal of Medicine 386 (7), 629-639, 2022 | 477 | 2022 |
| Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal … M Gnant, M Filipits, R Greil, H Stoeger, M Rudas, Z Bago-Horvath, ... Annals of oncology 25 (2), 339-345, 2014 | 470 | 2014 |
| Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial V Subbiah, U Lassen, E Élez, A Italiano, G Curigliano, M Javle, ... The Lancet Oncology 21 (9), 1234-1243, 2020 | 461 | 2020 |
Oliver HantschelAssistant Professor, EPFLZweryfikowany adres z epfl.ch
